Hemostemix (CVE:HEM) Trading Up 23.8% – Still a Buy?

by · The Cerbat Gem

Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 23.8% during trading on Wednesday . The stock traded as high as C$0.13 and last traded at C$0.13. 356,000 shares were traded during trading, an increase of 1% from the average session volume of 351,835 shares. The stock had previously closed at C$0.11.

Hemostemix Stock Performance

The stock’s fifty day simple moving average is C$0.09 and its two-hundred day simple moving average is C$0.07. The stock has a market capitalization of C$12.63 million, a P/E ratio of -7.25 and a beta of 0.20.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Recommended Stories